1Molldrem JJ, Jiang YZ, Stetler-Stevenson M, et al. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles [J]. Br J Haematol, 1998, 102 (5):1314.
2Sloand EM, Kim S, Fuhrer M, et al. Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities [ J ]. Blood, 2002, 100 ( 13 ) : 4427.
3Molldrem JJ, Caples M, Mavroudis D, et al. Antithymocyte globulin for patients with myelodysplastic syndrome [J]. BrJnaematol, 1997, 99 (3):699.
4Sugawara T, Endo K, Shishido T, et al. T cell-mediated inhibition of erythropoiesis in myelodysplastie syndromes [J]. Am J Hematol, 1992, 41 (4):304.
5Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes [ J ]. Ann Intern Med, 2002, 137 (3):156.
6Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow [ J ]. Br J Haematol, 1998, 100 (2):304.
7Shimamoto T, Tohyama K, Okamoto T, et al. Cyclosporin A therapy for patients with myelodyspiastic syndrome: Multicenter pilot studies in Japan [ J J. Leuk Res, 2003, 27 (9):783.
8Chen S, Jiang B, Da W, et al. Treatment of myelodysplastic syndrome with cyclosporin A [ J ]. Int J Hematol, 2007, 85 (1):11.
9Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha [J]. J Immunol, 1999, 163 (1):380.
10Epling-Burnette PK, Bai F, Painter JS, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NKreceptors [J]. Blood, 2007, 109 (11):4816.
